Results 111 to 120 of about 5,563 (240)

The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm [PDF]

, 2020
Bispecific T-cell engager (BiTE) molecules are designed to engage and activate cytotoxic T cells to kill tumor cells. Little is known about their biodistribution in immunocompetent settings.
Friedrich, Matthias, Lorenczewski, Grit, Stienen, Sabine, Suurs, Frans V, De Groot, Derk Jan A, Lub-de Hooge, Marjolijn N; id_orcid, de Vries, Elisabeth G E, de Vries, Elisabeth G E; id_orcid, Lub-de Hooge, Marjolijn N   +8 more
core   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Blinatumomab as a bridge to trasplantation in refractory Philadelphia chromosome negative b-cell acute lymphoblastic leukemia: a case report

Anales del Sistema Sanitario de Navarra, 2019
Blinatumomab is a first class bispecific T-cell engager that has been shown to achieve negative minimal residual disease in patients with relapsed or refractory pre-B acute lymphoblastic leukemia after conventional chemotherapy.
A. Rodríguez-Ferreras, I. Zapico-García   +1 more
doaj   +1 more source

The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types

, 2020
Immuno‐oncology therapies engage the immune system to treat cancer. BiTE (bispecific T‐cell engager) technology is a targeted immuno‐oncology platform that connects patients' own T cells to malignant cells.
Robert Z. Orlowski, Roboz, Gail J., Orlowski, Robert Z., Subklewe, Marion, Hermann Einsele, Gerhard Zugmaier, Zugmaier, Gerhard, Kantarjian, Hagop M., Borghaei, Hossein, Hossein Borghaei, Kufer, Peter, Gail J. Roboz, Iskander, Karim, Peter Kufer, Hagop M. Kantarjian, Marion Subklewe, Karim Iskander, Einsele, Hermann   +17 more
core   +1 more source

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

The Functional Role and Molecular Characterization of the Therapeutic Target CLDN6 in Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Background The tight junction protein CLDN6 has been identified as a cancer‐associated cell surface marker that is rarely expressed in healthy tissues. In testicular germ cell tumors (GCT), CLDN6 is particularly detectable in seminomas, embryonal carcinomas, and choriocarcinomas.
Jule Zwick, Margaretha A. Skowron, Gereon Poschmann, Patrick Petzsch, Ann Kathrin Bergmann, Kai Stühler, Jochen Hecht, Daniel Nettersheim   +7 more
wiley   +1 more source

Reactivating exhausted tumor-infiltrating T cells by a bispecific DC-T cell engager in mice

Nature Communications
Tumor infiltrating T cells (TIL) are key players in the anti-tumor immune response. However, chronic exposure to tumor-derived antigens drives the differentiation into ‘exhausted’ TILs.
Xuhao Zhang, Yu Gao, Wenbo Hu, Yong Liang, Xiaozhe Yin, Xiangjun Shi, Hongjia Li, Huiping Liao, Jingya Guo, Xiaohong Yu, Mingzhao Zhu, Hua Peng, Wenyan Wang, Yang-Xin Fu   +13 more
doaj   +1 more source

A bispecific gd T-cell engager targeting EGFR activates a potent Vg9Vd2 T cell-mediated immune response against EGFR-expressing tumors

, 2023
Vy9V82 T cells are effector cells with proven antitumor efficacy against a broad range of cancers. This study aimed to assess the antitumor activity and safety of a bispecific antibody directing Vy9V82 T cells to EGFR-expressing tumors.
Toffoli, E.C., Slot, M.C., Veth, M., Derks, S., Ruben, J.M., Fransen, M.F., Riedl, T., Amsen, D., Adang, A.E.P., King, L.A., Roovers, R.C., Iglesias-Guimarais, V., Parren, P.W.H.I., Gruijl, T.D. de, Tuynman, J.B., Ven, R. van de, Vliet, H.J. van der   +16 more
core   +1 more source

BiTE® T cell-dependent cellular cytotoxicity (TDCC) assay v1

, 2017
T cell dependent cytotoxicity assay for measuring bispecific T cell engager (BiTE®) activity.
not provided Gordon Moody, not provided Angela Coxon, not provided Patricia L. McElroy, not provided Julie A. Lofgren, not provided Tara Arvedson, Sandra L. Ross, not provided Marika Sherman, not provided Patrick A. Baeuerle   +7 more
core   +1 more source

Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost‐effectiveness analysis

British Journal of Haematology, EarlyView.
Summary To assess the cost‐effectiveness of blinatumomab plus chemotherapy for paediatric patients from Hong Kong public healthcare provider's perspective, a 10‐year Markov model was designed to simulate outcomes in paediatric patients with newly diagnosed standard‐risk B‐cell ALL at: (1) average risk and (2) high risk of relapse.
Mingjun Rui, Yin Ting Cheung, Hui Zhang, Qiran Wei, Yingcheng Wang, Jiaqi Shi, Chi Kong Li, Joyce H. S. You   +7 more
wiley   +1 more source